• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Cardiol . Abnormal apelin-ACE2 and SGLT2 signaling contribute to adverse cardiorenal injury in patients with COVID-19

tetano

Editor, Senior Moderator
Int J Cardiol


. 2021 May 14;S0167-5273(21)00841-X.
doi: 10.1016/j.ijcard.2021.05.029. Online ahead of print.
Abnormal apelin-ACE2 and SGLT2 signaling contribute to adverse cardiorenal injury in patients with COVID-19


Xue-Ting Li[SUP] 1 [/SUP], Mi-Wen Zhang[SUP] 1 [/SUP], Zhen-Zhou Zhang[SUP] 2 [/SUP], Yu-Dan Cao[SUP] 3 [/SUP], Xiao-Yan Liu[SUP] 1 [/SUP], Ran Miao[SUP] 4 [/SUP], Yuan Xu[SUP] 3 [/SUP], Xiao-Fang Song[SUP] 3 [/SUP], Jia-Wei Song[SUP] 1 [/SUP], Ying Liu[SUP] 1 [/SUP], Ying-Le Xu[SUP] 5 [/SUP], Jing Li[SUP] 6 [/SUP], Ying Dong[SUP] 6 [/SUP], Jiu-Chang Zhong[SUP] 7 [/SUP]



Affiliations

Abstract

Background: Angiotensin converting enzyme 2 (ACE2) has recently been identified as the functional receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent response for novel coronavirus disease 2019 (COVID-19). This study aimed to explore the roles of ACE2, apelin and sodium-glucose cotransporter 2 (SGLT2) in SARS-CoV-2-mediated cardiorenal damage.
Methods and results: The published RNA-sequencing datasets of cardiomyocytes infected with SARS-CoV-2 and COVID-19 patients were used. String, UMAP plots and single cell RNA sequencing data were analyzed to show the close relationship and distinct cardiorenal distribution patterns of ACE2, apelin and SGLT2. Intriguingly, there were decreases in ACE2 and apelin expression as well as marked increases in SGLT2 and endothelin-1 levels in SARS-CoV-2-infected cardiomyocytes, animal models with diabetes, acute kidney injury, heart failure and COVID-19 patients. These changes were linked with downregulated levels of interleukin (IL)-10, superoxide dismutase 2 and catalase as well as upregulated expression of profibrotic genes and pro-inflammatory cytokines/chemokines. Genetic ACE2 deletion resulted in upregulation of pro-inflammatory cytokines containing IL-1?, IL-6, IL-17 and tumor necrosis factor ?. More importantly, dapagliflozin strikingly alleviated cardiorenal fibrosis in diabetic db/db mice by suppressing SGLT2 levels and potentiating the apelin-ACE2 signaling.
Conclusion: Downregulation of apelin and ACE2 and upregulation of SGLT2, endothelin-1 and proinflammatory cytokines contribute to SARS-CoV-2-mediated cardiorenal injury, indicating that the apelin-ACE2 signaling and SGLT2 inhibitors are potential therapeutic targets for COVID-19 patients.

Keywords: Angiotensin converting enzyme 2; Apelin; COVID-19; Inflammation; SGLT2 inhibitor; Severe acute respiratory syndrome coronavirus 2.
 
Back
Top Bottom